Sublingual immunotherapy
- 31 March 2001
- journal article
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 107 (3), 441-444
- https://doi.org/10.1067/mai.2001.113525
Abstract
Recent claims have been made that sublingual immunotherapy (SLIT) may be a viable alternative to injection immunotherapy (SIT). Animal studies show that when allergens are administered topically, they are handled differently, and IgE responses can be reduced. Most published studies of human SLIT have been small but show fairly consistent benefits on symptom scores, with few systemic side effects. Objective measures of allergen reactivity usually do not change. Relatively few subjects have been treated in SLIT trials compared with the numbers that would be required to validate new drug therapies. On the plus side, SLIT appears to work in adults and in children; it offers some logistic advantages and seems to be safe. Giving allergen by mouth rather than by injection should decrease the costs of immunotherapy, but the cumulative dose of allergen used in SLIT has been between 20 to 375 times the dose given in conventional SIT. Further cost-benefit analysis is needed. On the other hand, standard SIT is effective and is supported by better clinical and experimental evidence. The balance sheet for SLIT is improving, but on the current evidence, SLIT requires further evaluation before it could be recommended for use in routine clinical practice. (J Allergy Clin Immunol 2001;107:441-4.)Keywords
This publication has 39 references indexed in Scilit:
- Local immunotherapyAllergy, 1998
- Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beingsJournal of Allergy and Clinical Immunology, 1997
- Antigen presenting capacity of Langerhans cells from rat oral epitheliumJournal of Oral Pathology & Medicine, 1995
- The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production.The Journal of Experimental Medicine, 1993
- Defence against allergic sensitization in the healthy lung: the role of inhalation toleranceClinical and Experimental Allergy, 1989
- The regulation of immune responses to dietary protein antigensImmunology Today, 1987
- IS HOMOEOPATHY A PLACEBO RESPONSE? CONTROLLED TRIAL OF HOMOEOPATHIC POTENCY, WITH POLLEN IN HAYFEVER AS MODELThe Lancet, 1986
- Low dose sublingual therapy in patients with allergic rhinitis due to house dust miteClinical and Experimental Allergy, 1986
- Absorption of antigens after oral immunisation and the simultaneous induction of specific systemic tolerance.Gut, 1979
- ORAL POLLEN THERAPY IN RAGWEED POLLINOSISJournal of the American Medical Association, 1940